BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up to date with the BeiGene hematology pipeline and clinical trials.

Factsheet outlining a new therapeutic approach for patients with B-cell malignancies who have become intolerant to certain BTKi therapies.

Factsheet describing a treatment option for relapsed/refractory (R/R) follicular lymphoma (FL) with a BTKi and an anti-CD20 monoclonal antibody.

Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

Factsheet describing the treatment of Waldenström's macroglobulinemia (WM) by inhibiting BTK.